Inactivation mechanism of cold plasma combined with 222 nm ultraviolet for spike protein and its application in disinfecting of SARS-CoV-2.

Publication date: Mar 05, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible virus that has precipitated a worldwide pandemic of coronavirus disease since 2019. Developing an effective disinfection strategy is crucial to prevent the risk of surface cross-contamination by SARS-CoV-2. This study employed pseudovirus and the receptor-binding domain (RBD) protein of SARS-CoV-2 as models to investigate the spike protein inactivation process and its underlying mechanisms using a novel nonthermal technology. Cold plasma combined with 222 nm ultraviolet (CP+UV) treatment was applied to accelerate the generation of reactive species and enhance sterilization efficiency. The results indicated that the binding activity of RBD protein was completely inhibited at specific concentrations (0. 01-0. 05 mg/cm) with corresponding treatment times of 15-30 s. The mechanism potentially involves the reactive species generated by CP+UV, which react with the spike protein RBD of SARS-CoV-2, leading to the loss of SARS-CoV-2 infectivity by causing damage to the β-sheet structure and chemical bonds in the RBD protein. Validated by a biosafety level 3 (BSL3) laboratory, the CP+UV treatment for 30 s could completely inactivate SARS-CoV-2 with a concentration of 19054 +/- 1112 TCID/cm. Therefore, this study potentially provides a novel disinfection strategy for the inactivation of SARS-CoV-2 on surface cross-contamination.

Concepts Keywords
Biosafety 222 nm ultraviolet
Cold Cold plasma
Coronavirus COVID-19
Pandemic Humans
Inactivation mechanism
Plasma Gases
Plasma Gases
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
Spike protein RBD
spike protein, SARS-CoV-2


Type Source Name
disease VO inactivation
disease VO Severe acute respiratory syndrome coronavirus 2
pathway KEGG Coronavirus disease
disease VO effective
disease IDO process
disease VO efficiency
disease IDO infectivity
disease MESH COVID-19
disease VO Glycoprotein

Original Article

(Visited 1 times, 1 visits today)